Alessandro Albuquerque

About Alessandro Albuquerque

With over 15 years in medical affairs and clinical development, I lead Recordati\'s medical organization as Chief Medical Officer, overseeing rare disease franchises in metabolic, endocrinology, hematology, and oncology. My work integrates clinical operations, pharmacovigilance, RWE/HEOR, and medical affairs to streamline performance, supported by precise metrics that highlight organizational impact. At Recordati, we introduced an AI-powered geo-targeted IME/CME strategy based on claims data and HCP profiling, driving a 300% increase in educational investment within a year. Passionate about leveraging technology and collaboration, I focus on delivering innovative solutions to improve patient care and advance medical practices in rare diseases.

Experience

1. Chief Medical Officer and Vice President Medical Affairs & Clinical Development

   Recordati

   Jul 2024 — Present · Bridgewater, NJ, US

   Pioneered the strategic integration of all functions within the medical organization, encompassing medical affairs across four rare disease franchises (metabolic, endocrinology, hematology, and oncology), clinical operations, clinical development, medical information & operations, pharmacovigilance, and RWE/HEOR. This initiative led to a high-performing medical organization that reports performance with precise metrics to demonstrate significant impact.• Spearheaded the development of the first IME/CME geo-targeted approach based on claims data and HCP profiling, resulting in a 300% increase in CME/IME investment within one year.• Innovatively implemented AI-generated profiling to guide the next best interactions with HCPs across North America, integrating all MSL available materials and successfully deploying AI-generated actionable insights.• Orchestrated the substantial expansion of the medical organization by integrating new functions and hiring the right talent, guided by predictive index to ensure optimal fit within the organization.• Successfully launched five major RCTs in rare diseases, including the deployment of sites across the United States.• Introduced three new indications, including the expansion of Osilodrostat, the first-generation aldosterone synthase inhibitor.• Coordinated five successful cross-functional interactions with the FDA for new label indications and label enhancements based on RWE, and achieved three successful FDA audits on clinical trials.• Seamlessly integrated the field-based medical team into a new compliant metrics operating model

Education

• Università degli Studi di Trieste

  Doctor of Philosophy - PhD, Molecular Genetics

• Universidade Federal do Pará

  Medical Degree (MD), Medicine

• Tufts University

  Post-Graduate Course in Clinical Pharmacology, Drug Development, and Regulation, Medicine

Skills

• Molecular Genetics
• Healthcare
• Anesthesia
• Critical Care
• Market Access
• Health Economics
• Clinical Trials
• Medical Devices
• Clinical Research
• Biotechnology
• Medical Research
• Enteral Nutrition
• Product Launch
• Pharmaceutical Industry
• Cross-Functional Team Leadership
• Genetic Engineering
• Geographic Expansion
• Medical Affairs
• Medical Education
• Parenteral Nutrition